I have been searching for a formula on how to build a good dividend portfolio of large-cap dividend stocks that can outperform the market by a significant margin on the long run. After many trials, I have found out that a portfolio of twenty S&P 500 companies yielding more than two percent a year and having the highest Research and Development Expense to Revenue ratio is giving excellent results.
I used Portfolio123’s screener to perform the search and to run back-tests according to these conditions. After running this screen on 19 August 2017, I discovered the following twenty stocks, which are shown in tables below.
It is worth noting that pharmaceuticals and biotechnology companies account for forty percent of the companies in the above list, and semiconductors & semiconductor equipment companies account for twenty-five percent of the companies. As I see it, that is not surprising since these industries are very sophisticated and require massive research and development expenses.
The table below presents the research and development expense for the last twelve months (TTM), the revenue TTM and the research and development to revenue ratio, for the leading twenty companies.
In order to find out how such a screening formula would have performed during the last two years, last ten years and last nineteen years, I ran the back-tests, which are available by the Portfolio123’s screener.
The back-test takes into account running the screen once a year and replacing the stocks that no longer comply with the screening requirement with other stocks that comply with the requirement. The theoretical return is calculated in comparison to the benchmark (S&P 500), considering 0.25% slippage for each trade and 1.5% annual carry cost (broker cost). The back-tests results are shown in the charts and the tables below.
Two years back-test
Ten years back-test
Nineteen years back-test
The dividend stocks portfolio based on the highest research and development expense to revenue ratio among all S&P 500 companies has given much better returns during the last two years, the past ten years and the last nineteen years than the S&P 500 benchmark. The Sharpe ratio, which measures the ratio of reward to risk, was also much better in all the three tests.
The two years average annual return of the dividend stocks portfolio was at 15.75%, while the average annual return of the S&P 500 index during the same period was at 7.56%. The difference between the dividend stocks portfolio based on the highest research and development expense to revenue ratio to the benchmark was even more noticeable in the nineteen years back-test. The nineteen years average annual return of the dividend stocks portfolio was at 12.36%, while the average annual return of the S&P 500 index during the same period was only 3.72%. What is most important, the maximum drawdown of the dividend stocks portfolio during that time was only at 38.17%, while that of the S&P 500 was at 57%.
Although this dividend stocks portfolio based on the highest research and development expense to revenue ratio has given superior results, I recommend readers use this list of stocks as a basis for further studies.
DISCLAIMER: This article expresses my own ideas and opinions. Any information I have shared are from sources that I believe to be reliable and accurate. I did not receive any financial compensation in writing this post, nor do I own any shares in any company I’ve mentioned. I encourage any reader to do their own diligent research first before making any investment decisions.
BB Biotech: Positive development in a volatile market environment
The total shareholder return in 2020 was 19.3% in CHF and 18.1% in EUR, slightly below the performance of the...
Bitcoin slips back to $53,000 and major altcoins go lower on February 22nd
The fall seen in the price of Bitcoin on February 22 was also strongly felt among exponents such as Ethereum...
The keys to ESG investment in 2021 in the face of growing interest and profitability
While all the data point to the fact that investment under climate, social and corporate governance criteria is increasingly in...
New investments in the Fez-Meknes Region
As part of the industrial revival strategy, the Fez-Meknes Region should welcome 95 potential projects identified in the project bank....
Rebound in pharma and healthcare operations: 14% increase in 2020
The volume of mergers and acquisitions in the pharmaceutical and healthcare sector increased by 25% compared to the first half...
Featured7 days ago
Banca Progetto prepares to launch instant lending for consumer credit
Cannabis6 days ago
The ANMAT will allow the importation of cannabis-based products in Argentina
Featured7 days ago
Repsol hires Linklaters and Uría to list its renewable energy subsidiary
Crypto5 days ago
How LODEpay’s Price Oracle is Tackling Silver Spot Price Manipulation